[{"id":"a1596462-69b2-4cbb-bcf0-d0bed5de43d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02508467","created_at":"2021-01-18T12:06:37.223Z","updated_at":"2024-07-02T16:35:09.856Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT02508467","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 07/31/2015","start_date":" 07/31/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-12"},{"id":"8618c3fa-4468-4945-aa54-0b000144497e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04194801","created_at":"2023-02-06T18:00:21.094Z","updated_at":"2024-07-02T16:35:56.405Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT04194801","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cejemly (sugemalimab) • fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/16/2019","start_date":" 12/16/2019","primary_txt":" Primary completion: 10/20/2021","primary_completion_date":" 10/20/2021","study_txt":" Completion: 10/20/2021","study_completion_date":" 10/20/2021","last_update_posted":"2023-02-06"}]